Pharmaceutical industry – Page 49
-
Business
Vertex to cut 370 jobs
Imminent competition drives drop in its hepatitis C drug’s performance
-
Business
AstraZeneca to close environmental lab and cut 71 jobs
Environmental impact services will be outsourced after Devon lab closes in March 2014
-
Business
Pharma manufacturing woes dog industry
Regulators are stepping up inspections, and discovering ever more problems
-
Business
Counterfeit anxiety pills seized in Switzerland
1 million fake tablets were en route from China to Egypt
-
Business
Roche backs biologics boom
Swiss firm to invest heavily in manufacturing for complex biological drugs
-
-
Business
GSK to apply for malaria vaccine approval
Infection protection drops over time, but the firm will go ahead with regulatory submission
-
Business
Lundbeck cuts jobs in Europe, but expands in US
Depression drug approval fuels US recruitment
-
Business
Amid huge cuts, Merck vows research focus
8500 more jobs to be axed, but the drugmaker ‘remains committed to innovation’
-
Business
Aspen acquires anticoagulant brands
South African drugmaker buys thrombosis drugs from GSK for £700m
-
Business
Japan confirms Novartis clinical trial data fabrication
Investigation into blood pressure blockbuster continues
-
Business
New respiratory drugs neck and neck
Combination inhalers from GSK and Novartis approved in EU and Japan
-
Business
Nanobody inflammation drug attracts Abbvie
$840m licensing deal shows support for antibody fragments
-
Careers
Non-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates
-
Business
Service with a smile
Company profile: Charnwood Molecular is more than a run-of-the-mill contract synthesis provider
-
Business
GSK criticised for trial data secrecy
Italian research institute abandons collaboration over data access
-
Business
First biosimilar antibody drugs approved in Europe
European commission gives final approval to generic infliximab copies
-
Business
Otsuka to buy Astex for $886 million
Japanese firm intends to leave Astex’s fragment-based R&D efforts intact
-
Business
Amgen snaps up Onyx in huge biotech deal
$10.4 billion acquisition will expand firm’s oncology portfolio
-
Business
Lundbeck appeals European antitrust fine
Danish pharmaceutical claims €93.8 million pay-for-delay penalty was the result of ‘serious legal and factual errors’